Evaluation of the patient with pleural effusion

Beaudoin, Stéphane; Gonzalez, Anne V.

doi:10.1503/cmaj.170420

Cited by 62 publications

(86 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Excess fluid formation in the pleural space occurs because of many different reasons, which can be either malignant or benign [5]. When treating pleural effusion, the physician must determine whether it is a transudate or exudate.…”

Section: Pleural Effusionmentioning

confidence: 99%

“…Light criteria correctly identify all exudates, whereas transudates are approximately 25% of cases falsely defined as exudates. These mistakes happen mostly in patients with heart failure or liver cirrhosis, who are receiving diuretics [5,8]. In such cases, serum-pleural effusion albumin gradient (SAAG) values can be of additional help [13,14].…”

Section: Pleural Effusionmentioning

confidence: 99%

“…The most common cause being heart failure. The treatment of transudate effusion is aimed at the elimination of the causing agents [5]. The treatment in exudates is, in comparison, much more aggressive.…”

Section: Pleural Effusionmentioning

confidence: 99%

“…The level of severity of the accompanying symptoms depends on the amount/volume of the effusion and the patients’ cardiopulmonary state. Just recently, after seven years, the new guidelines for the management of MPE were published by the European respiratory society (ERS/EACT) and the collaboration of American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology (ATS/STS/STR) [5]. At the same time, new findings regarding the pathophysiology of MPE were discovered.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Malignant Pleural Effusion and Its Current Management: A Review

et al. 2019

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease. It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent. Additionally, the process of pathogenesis is greatly affected by activating mutations of EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK and RET, which correlate with an increased incidence of MPE. Considering all these changes, the authors aim to present a literature review of the newest findings, review of the guidelines and pathophysiological novelties in this field. Review of the just recently, after seven years published, practice guidelines, as well as analysis of more than 70 articles from the Pubmed, Medline databases that were almost exclusively published in indexed journals in the last few years, have relevance and contribute to the better understanding of the presented topic. MPE still presents a severe medical condition in patients with advanced malignancy. Recent findings in the field of pathophysiological mechanisms of MPE emphasize the role of molecular factors and mutations in the dynamics of the disease and its prognosis. Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. The current guidelines address multiple areas of interest bring novelties in the form of validated prediction tools and can, based on evidence, improve patient outcomes. However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.

show abstract

Section: Pleural Effusionmentioning

confidence: 99%

Section: Pleural Effusionmentioning

confidence: 99%

Section: Pleural Effusionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Malignant Pleural Effusion and Its Current Management: A Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Pathogenesis of pleural effusion with exudates needs to be extensively investigated for so many causes will lead to the disease. [1] Pleural malignant disease and tuberculosis pleurisy are 2 challenging conditions to identify when facing with recurrent undiagnosed exudate. [1–3] The annual incidence was about 15,000 cases in the year of 2000 for malignant pleural effusion (MPE) in the United States, [4] and MPE shortened the life expectancy of lung cancer patients, severely, [5] but there is no beneficial fluid biomarker for clinical use for MPE.…”

Section: Introductionmentioning

confidence: 99%

High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion

Zhang

2019

Medicine

View full text Add to dashboard Cite

show abstract

Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value

Shaker

Abid³

2022

Diagnostic Cytopathology

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy with a poor prognosis. Because of this tumor rarity and overlapping histologic features with other malignancy types, the histopathological findings and diagnostic immunohistochemical workup are essential in establishing the final diagnosis of MPMs. We aimed to review the diagnostic criteria, WHO tumor classification updates, and immunohistochemical staining markers diagnostic value to achieve an appropriate clinical diagnosis.

show abstract

Evaluation of the patient with pleural effusion

Cited by 62 publications

References 35 publications

Malignant Pleural Effusion and Its Current Management: A Review

Malignant Pleural Effusion and Its Current Management: A Review

High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion

Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value

Contact Info

Product

Resources

About